Spelling suggestions: "subject:"[een] KIDNEY TRANSPLANTATION"" "subject:"[enn] KIDNEY TRANSPLANTATION""
1 |
Post-discharge adjustment among renal transplant recipients and their spouse/partnersEvers-Mahoney, Cheryl Ann. January 1992 (has links)
Thesis (M.S.)--University of Wisconsin-Madison, 1992. / Typescript. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references (leaves 77-84).
|
2 |
Development of a model of chronic rejection in rat renal allograftsGraudenz, Marcia Silveira January 1993 (has links)
No description available.
|
3 |
Isolation and characterization of dendritic leukocytes from mouse kidneyRao, Abdul Sohail Khan January 1992 (has links)
No description available.
|
4 |
An investigation of EPO as a tissue protective agent in human kidney transplantationDe Freitas, Declan January 2011 (has links)
Ischaemia-reperfusion injury (IRI) has been identified as a major contributor to both short and long term kidney transplant failure. Experimental evidence from the literature suggests that Erythropoietin (EPO) is tissue protective, reducing both inflammation and apoptosis following IRI. We performed a randomised, double blind, placebo controlled trial examining the tissue protective effect of high dose EPO (100,000iu over 3 days) in 39 recipients of an extended criteria donor kidney or a non-heart-beating donor kidney. The primary endpoints of the study were difference in plasma and urinary biomarker levels (NGAL, IL-18 and KIM-1) in addition to changes in gene expression. Secondary endpoints included safety, clinical data and differences in metabolomics profiles. There was no difference detected between the treatment groups in terms of biomarkers, gene expression, metabolomics profiling or clinical parameters. No adverse events related to EPO therapy were recorded. In addition, we developed a cell model of kidney transplantation using primary tubulo-epithelial cells and HMEC-1 cells, with which to confirm the protective effects of EPO. Treatment with 50U/ml one hour prior to undergoing cold hypoxia resulted in the maximum degree of tissue protection, as measured using an MTT and an LDH assay. No evidence of EPO toxicity was demonstrated. Tubulo-epithelial cells expressed EPOR mRNA and protein. No CD131 receptor could be demonstrated. In summary, EPO confers tissue protection in a cell model of kidney transplantation but this has not been shown to occur in a clinical trial using high dose EPO in recipients of marginal donor kidneys.
|
5 |
Role BAFF cytokinu v transplantačních reakcích / Role of BAFF cytokine in transplantation reactonsSekerková, Zuzana January 2016 (has links)
Current immunogenetic tests before organ transplantation include HLA typing and detection of HLA-specific antibodies. However, these tests do not provide information about the B cells participating in the humoral response against the transplanted organ. BAFF (B activating factor) plays an important role in the proliferation, maturation and differentiation of B cells. A soluble form of the cytokine arises after splicing the membrane form of BAFF. The soluble cytokine binds to three types of receptors - TACI, BCMA and BCMA. Some recent studies suggest that BAFF could serve as a marker or predictor of antibody-mediated (humoral) rejection in kidney transplant recipients. Our study consists of two parts. The first part is focused on the detection of soluble BAFF levels in patients after renal transplantation. The aim of our study was therefore to correlate levels of soluble BAFF cytokine in patients before and after transplantation with the clinical course and incidence of rejection after transplantation. The study included 92 kidney recipients. Humoral rejection was diagnosed on the basis of a positive finding of C4d deposits in peritubular capillaries (imunoflorescenční detection), and the presence of donor- specific antibodies. BAFF levels were determined using Xmap methodology by the Luminex method...
|
6 |
Expectations of renal transplant recipients and their significant others regarding returning to work a research report submitted in partial fulfillment ... /Newton, Sarah Elizabeth. January 1987 (has links)
Thesis (M.S.)--University of Michigan, 1987.
|
7 |
Nursing care for kidney donors what can nursing do to provide a healthy experience? : a retrospective view : a report submitted in partial fulfillment ... for the degree of Master of Science (Medical Surgical Nursing) ... /Walton, Patricia L. January 1995 (has links)
Thesis (M.S.)--University of Michigan, 1995. / Includes bibliographical references.
|
8 |
Expectations of renal transplant recipients and their significant others regarding returning to work a research report submitted in partial fulfillment ... /Newton, Sarah Elizabeth. January 1987 (has links)
Thesis (M.S.)--University of Michigan, 1987.
|
9 |
Nursing care for kidney donors what can nursing do to provide a healthy experience? : a retrospective view : a report submitted in partial fulfillment ... for the degree of Master of Science (Medical Surgical Nursing) ... /Walton, Patricia L. January 1995 (has links)
Thesis (M.S.)--University of Michigan, 1995. / Includes bibliographical references.
|
10 |
Blood transfusion and HLA in renal transplantation prolonged graft survival related to disparity in HLA-A antigens /Bućin, Dragan. January 1994 (has links)
Thesis (doctoral)--Lund University, 1994. / Added t.p. with thesis statement inserted.
|
Page generated in 0.0416 seconds